ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
JCI Publishes Preclinical Study Evaluating Potential Ability Of CVT-6883 For The Treatment Of Pulmonary Conditions
CV Therapeutics,
Inc. (Nasdaq: CVTX) announced today that the Journal of Clinical
Investigation (JCI) has published a preclinical study suggesting that
CVT-6883 significantly reduced elevated markers of inflammation, fibrosis
and pulmonary injury in two separate in vivo models.
CVT-6883 is a selective, potent and orally available A2B-adenosine
receptor antagonist which CV Therapeutics is investigating for the
potential treatment of asthma and other conditions related to inflammation
and fibrosis.
An initial Phase 1 study of CVT-6883 has been completed. In this
randomized, double-blind, placebo-controlled, single ascending dose study
in 24 healthy volunteers, CVT-6883 was well tolerated with no serious
adverse events reported.
In the preclinical study described in JCI, mice predisposed to elevated
adenosine levels developed pulmonary inflammation, fibrosis and enlargement
of air sacs in the lungs called alveolar spaces. Treatment with CVT-6883
reduced these conditions and also significantly reduced elevations in
proinflammatory cytokines and chemokines. In a separate in vivo model,
CVT-6883 also inhibited pulmonary inflammation and fibrosis induced by
bleomycin.
"These in vivo models exhibit many of the characteristics typical of
patients with chronic lung disease and asthma, so the results support the
scientific rationale for treating asthma and other conditions related to
inflammation and fibrosis with a selective A2B-adenosine receptor
antagonist," said Michael Blackburn, Ph.D., professor of biochemistry and
molecular biology at the University of Texas Medical School at Houston and
corresponding author of the study.
About Asthma
Asthma is a chronic lung disease characterized by recurrent episodes of
wheezing, breathlessness, chest tightness and coughing. Pulmonary
inflammation contributes to the bronchoconstriction that can precipitate an
asthma attack and to the progression of this chronic disease.
In 2002, 20 million people in the United States had asthma, according
to the American Lung Association. The National Heart Lung and Blood
Institute notes that asthma accounts for $16.1 billion in direct and
indirect healthcare costs annually.
In asthma, increased levels of adenosine can overactivate the A2B-
adenosine receptor leading to mast cell degranulation and the release of
inflammatory cytokines associated with bronchoconstriction and chronic lung
inflammation. CVT-6883 may provide a potentially novel approach to
preventing or reducing this inflammatory process by selectively inhibiting
the A2B- adenosine receptor.
About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a
biopharmaceutical company focused on applying molecular cardiology to the
discovery, development and commercialization of novel, small molecule drugs
for the treatment of cardiovascular diseases.
CV Therapeutics' approved products include Ranexa(R) (ranolazine
extended- release tablets) and ACEON(R) (perindopril erbumine) Tablets.
Ranexa is indicated for the treatment of chronic angina in patients who
have not achieved an adequate response with other antianginal drugs, and
should be used in combination with amlodipine, beta-blockers or nitrates.
In addition, CV Therapeutics co-promotes ACEON(R), an ACE inhibitor, for
reduction of the risk of cardiovascular mortality or nonfatal myocardial
infarction in patients with stable coronary artery disease and treatment of
essential hypertension.
CV Therapeutics also has other clinical and preclinical drug
development candidates and programs, including regadenoson, which is being
developed for potential use as a pharmacologic stress agent in myocardial
perfusion imaging studies and CVT-6883, which is being developed as a
potential treatment for asthma and other conditions. Regadenoson and
CVT-6883 have not been determined by any regulatory authorities to be safe
or effective in humans for any use.
Except for the historical information contained herein, the matters set
forth in this press release, including statements as to development,
conduct of clinical studies, and study results, are forward-looking
statements within the meaning of the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to risks and uncertainties that may cause actual
results to differ materially, including, early stage of development;
regulatory review and approval of our products; the conduct and timing of
clinical trials; commercialization of products; market acceptance of
products; product labeling; and other risks detailed from time to time in
CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q
for the quarter ended March 31, 2006. CV Therapeutics disclaims any intent
or obligation to update these forward- looking statements.
CV Therapeutics, Inc.
http://www.cvt.com
View drug information on Ranexa.
JCI publicã preclinice de studiu de evaluare Potential de capacitatea de FPC-6883 pentru tratamentul pulmonarã condiþii - JCI Publishes Preclinical Study Evaluating Potential Ability Of CVT-6883 For The Treatment Of Pulmonary Conditions - articole medicale engleza - startsanatate